jnj-77242113
Peptideexperimental
Clinical trial activity
16 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
13
Phase 3
10
Phase 4
0
Earliest trial started Oct 25, 2021 (NCT05062200)
Timeline
Indications
Mechanism of action
- Interleukin-23 receptorANTAGONIST
antagonist - IL23R
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL6068124 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07196722 | Phase 2/Phase 3 (Phase 3) | Oct 3, 2025 | — |
| NCT07196748 | Phase 3 | Oct 1, 2025 | — |
| NCT06934226 | Phase 3 | Apr 15, 2025 | — |
| NCT06878404 | Phase 3 | Feb 21, 2025 | — |
| NCT06807424 | Phase 3 | Jan 9, 2025 | — |
| NCT06220604 | Phase 3 | Mar 9, 2024 | — |
| NCT06295692 | Phase 3 | Feb 9, 2024 | Janssen Pharmaceutica NV |
| NCT06143878 | Phase 3 | Feb 5, 2024 | — |
| NCT06095115 | Phase 3 | Oct 12, 2023 | — |
| NCT06095102 | Phase 3 | Oct 12, 2023 | — |
| NCT06049017 | Phase 2 | Oct 9, 2023 | — |
| NCT05703841 | Phase 1 | Feb 14, 2023 | — |
| NCT05357755 | Phase 2 | Jun 13, 2022 | — |
| NCT05364554 | Phase 2 | Jun 10, 2022 | — |
| NCT05223868 | Phase 2 | Feb 3, 2022 | — |
| NCT05062200 | Phase 1 | Oct 25, 2021 | Janssen Pharmaceutica NV |
Showing 16 of 16 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Janssen Pharmaceutica NV | For profit | 2 | 2 | 2 | 2021 |
1 organizations
Page 1 / 1